Insulin lispro: A fast-acting insulin analog

American Family Physician

Volumn 57, Issue 2, 1998, Pages 279-286

  Noble, Sara L ^a   Johnston, Elizabeth ^a   Walton, Bill ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN LISPRO;

BLOOD GLUCOSE MONITORING; CARBOHYDRATE METABOLISM; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN ALLERGY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LIPODYSTROPHY; REVIEW; SKIN ABSORPTION; SUBCUTANEOUS DRUG ADMINISTRATION;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT EDUCATION;

EID: 0031890881     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized, prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
3. Mazze RS, Etzwiler DD, Strock E, Peterson K, McClave CR II, Meszaros JF, et al. Staged diabetes management. Toward an integrated model of diabetes care. Diabetes Care 1994;17(Suppl 1):S56-S66.
4. Hirsch I, Farkas-Hirsch R. Type I diabetes and insulin therapy. Nurs Clin North Am 1993;28:9-23.
5. Campbell RK, Campbell LK, White JR. Insulin lispro: its role in the treatment of diabetes mellitus. Ann Pharmacother 1996;30:1263-71.
6. Galloway JA. New directions in drug development: mixtures, analogues, and modeling. Diabetes Care 1993;16(Suppl 3):S16-S23.
7. Zinman B. Insulin regimens and strategies for IDDM. Diabetes Care 1993;16(Suppl 3):S24-S8.
8. Ginsberg BH. The role of technology in diabetes therapy. Diabetes Care 1994;17(Suppl 1):S50-S55.
9. Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am 1996;25:243-54.
10. Betz JL. Fast-acting human insulin analogs: a promising innovation in diabetes care. Diabetes Educ 1995;21:195,197-8,200.
11. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402.
12. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994;37:713-20.
13. Johnson MD, White JR, Campbell RK. Insulin therapy in the era of insulin analogs. U.S. Pharmacist 1996;21:HS35-HS44.
14. Physicians' desk reference. Montvale, N.J.: Medical Economics, 1997:1488-90,1846-7.
15. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995;58:459-69.
16. Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? [Letter]. Diabet Med 1995;12:449-50.
17. Trautmann ME. Effect of the insulin analogue [LYS(B28),PRO(B29)] on blood glucose control. Horm Metab Res 1994;26:588-90.
18. Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 1995;18:1452-9.
19. Bignati L, Anderson J, Brunelle R, Jefferson F, Richardson M. Improvement of glycemic control with the rapidly absorbed lispro analog in type 1 diabetes. In: Abstracts of the 30th annual meeting of the European Association for the Study of Diabetes. Diabetologia 1994;37(Suppl 1):A78.
20. American Diabetes Association. Standards of medical care for patients with diabetes mellitus [Position statement]. Diabetes Care 1996,19(Suppl 1):S8-S15.
21. American Diabetes Association. Clinical practice recommendations 1997 [Position statement]. Diabetes Care 1997;20(Suppl 1):S1-S70.
22. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-3.
23. 1997 drug topics red book. Montvale, N.J.: Medical Economics, 1997.
24. Burge MR, Castillo KR, Schade DS. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care 1997;20:152-5.
25. Brunelle R, Anderson J, Vignati L. Decreased rate of hypoglycemia in association with improved metabolic control with insulin lispro. In: Abstracts of the 30th annual meeting of the European Association for the Study of Diabetes. Diabetologia 1994;37(Suppl 1):A78.
26. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care 1994;17:734-55.
27. Hypoglycemia. In: Peragallo-Dittko V, Godley K, Meyer J, eds. A core curriculum for diabetes education. 2d ed. Chicago: American Association of Diabetes Educators, 1993:351-72.
28. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 1991;8:217-22.
29. Tuominen JA, Karonen SL, Melamies L, Bolli G, Koivisto VA. Exercise-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995;38:106-11.
30. Anderson J, Symanowski S, Brunelle R. Safety of [Lys(B28), Pro(B290]: human insulin analog in long-term clinical trials [Abstract]. In: American Diabetes Association, 54th annual meeting. Diabetes 1994;43(Suppl 1):1A-269A.
31. Crowley M, Alexander W, Cassar D, Hitman G, James J, Kesson C, et al. Insulin lispro improves postprandial blood glucose control in type 1 and type 2 diabetes without increasing frequency of hypoglycemia [Abstract]. In: British Diabetic Association's Education and Professional Care Section annual conference and Medical and Scientific Section autumn meeting. Diabet Med 1995:12(10 Suppl 2):S33.
32. Koivisto VA. Insulin therapy in type II diabetes. Diabetes Care 1993;16(Suppl 3):S29-S39.
33. Bohannon NJ. Benefits of lispro insulin: control of postprandial glucose levels is within reach. Postgrad Med 1997;101(2):73-6,79-80.